Cheng Du

482 total citations
21 papers, 370 citations indexed

About

Cheng Du is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Cheng Du has authored 21 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Cheng Du's work include MicroRNA in disease regulation (4 papers), Ferroptosis and cancer prognosis (4 papers) and Ion channel regulation and function (3 papers). Cheng Du is often cited by papers focused on MicroRNA in disease regulation (4 papers), Ferroptosis and cancer prognosis (4 papers) and Ion channel regulation and function (3 papers). Cheng Du collaborates with scholars based in China, United States and Australia. Cheng Du's co-authors include Zhendong Zheng, Man‐Jiang Xie, Wenchao Liu, Baolei Li, Danqi Li, Meiling Wang, Xin Guan, Xiaodong Xie, Xiaodong Xie and Na Li and has published in prestigious journals such as PLoS ONE, Oncogene and Scientific Reports.

In The Last Decade

Cheng Du

19 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cheng Du China	12	235	96	83	55	50	21	370
Sofie Martens Belgium	8	424 1.8×	120 1.3×	99 1.2×	95 1.7×	23 0.5×	9	561
Su Yan China	11	290 1.2×	183 1.9×	121 1.5×	24 0.4×	53 1.1×	19	608
Qifei Zou China	11	240 1.0×	136 1.4×	147 1.8×	50 0.9×	37 0.7×	18	527
Stefania Gastaldi Italy	6	179 0.8×	97 1.0×	32 0.4×	43 0.8×	36 0.7×	6	317
Dianren Xia United States	10	314 1.3×	114 1.2×	120 1.4×	46 0.8×	45 0.9×	17	487
Yani Lin China	16	364 1.5×	81 0.8×	177 2.1×	55 1.0×	25 0.5×	44	555
Jacqueline Sayyah United States	9	368 1.6×	178 1.9×	78 0.9×	47 0.9×	35 0.7×	11	534
Yanqiu Song China	13	268 1.1×	125 1.3×	104 1.3×	61 1.1×	30 0.6×	34	445
Zicheng Sun China	10	232 1.0×	144 1.5×	107 1.3×	95 1.7×	49 1.0×	17	456
Dominique R. Talbert United States	7	239 1.0×	70 0.7×	58 0.7×	40 0.7×	20 0.4×	8	401

Countries citing papers authored by Cheng Du

Since Specialization

Citations

This map shows the geographic impact of Cheng Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng Du more than expected).

Fields of papers citing papers by Cheng Du

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheng Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng Du. The network helps show where Cheng Du may publish in the future.

Co-authorship network of co-authors of Cheng Du

This figure shows the co-authorship network connecting the top 25 collaborators of Cheng Du. A scholar is included among the top collaborators of Cheng Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheng Du. Cheng Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yan, Jing, Xi-sheng Shan, Jun Qian, et al.. (2025). Effect of music intervention on preoperative anxiety, a randomised clinical study. Scientific Reports. 15(1). 34261–34261.

Li, Guangyue, Shah Jehan, Cheng Du, et al.. (2024). β-caryophyllene sensitizes hepatocellular carcinoma cells to chemotherapeutics and inhibits cell malignancy through targeting MAPK signaling pathway. Frontiers in Pharmacology. 15. 1492670–1492670. 3 indexed citations

Li, Na, et al.. (2024). Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER. PLoS ONE. 19(4). e0299504–e0299504.

Gao, Xiaoli, et al.. (2024). Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy. Supportive Care in Cancer. 32(6). 370–370. 3 indexed citations

Li, Yingchun, Lili Cui, Zhenyong Zhang, et al.. (2024). Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer. Frontiers in Immunology. 15. 1364728–1364728. 3 indexed citations

Chen, Peng, et al.. (2024). Knockdown of ZNF280A inhibits cell proliferation and promotes cell apoptosis of bladder cancer.. PubMed. 39(3). 367–379. 2 indexed citations

Zhu, Dantong, Yao Liu, Meiling Wang, et al.. (2023). NPLOC4 is a potential target and a poor prognostic signature in lung squamous cell carcinoma. Scientific Reports. 13(1). 20430–20430. 2 indexed citations

Dong, Zehua, Lianlian Wu, Yanxia Li, et al.. (2022). A deep-learning based system using multi-modal data for diagnosing gastric neoplasms in real-time (with video). Gastric Cancer. 26(2). 275–285. 20 indexed citations

Du, Cheng, Xin Guan, Yao Liu, et al.. (2022). Disulfiram/copper induces antitumor activity against gastric cancer cells in vitro and in vivo by inhibiting S6K1 and c-Myc. Cancer Chemotherapy and Pharmacology. 89(4). 451–458. 26 indexed citations

10.

Guan, Xin, Meiling Wang, Yutong Chen, et al.. (2022). Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways. Bioengineered. 13(3). 6579–6589. 41 indexed citations

11.

He, Long, et al.. (2021). Rab6c is a new target of miR‑218 that can promote the progression of bladder cancer. Molecular Medicine Reports. 24(5). 3 indexed citations

12.

Du, Cheng, Xin Guan, Xiaowei Du, et al.. (2020). Asprosin is associated with anorexia and body fat mass in cancer patients. Supportive Care in Cancer. 29(3). 1369–1375. 17 indexed citations

13.

Liu, Lu, et al.. (2018). The role of BKCa in endometrial cancer HEC-1-B cell proliferation and migration. Gene. 655. 42–47. 18 indexed citations

14.

Du, Cheng, Danqi Li, Na Li, et al.. (2017). DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway. Scientific Reports. 7(1). 42876–42876. 47 indexed citations

15.

Du, Cheng, Zhendong Zheng, Danqi Li, et al.. (2016). BKCa promotes growth and metastasis of prostate cancer through facilitating the coupling between αvβ3 integrin and FAK. Oncotarget. 7(26). 40174–40188. 33 indexed citations

16.

Du, Cheng, Wenchao Liu, Tao Han, et al.. (2014). MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway. BMC Cancer. 14(1). 869–869. 37 indexed citations

17.

Chen, Lei, Cheng Du, Liang Wang, et al.. (2014). Human positive coactivator 4 (PC4) is involved in the progression and prognosis of astrocytoma. Journal of the Neurological Sciences. 346(1-2). 293–298. 18 indexed citations

18.

Munugalavadla, Veerendra, Sanjeev Mariathasan, Dionysos Slaga, et al.. (2013). The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene. 33(3). 316–325. 37 indexed citations

19.

Du, Cheng, et al.. (2013). Autologous cytokine-induced killer cells combined with chemotherapy in the treatment of advanced colorectal cancer: a randomized control study. The Chinese-German Journal of Clinical Oncology. 12(10). 487–491. 8 indexed citations

20.

Ma, Yu‐Guang, Wenchao Liu, Shuo Dong, et al.. (2012). Activation of BKCa Channels in Zoledronic Acid-Induced Apoptosis of MDA-MB-231 Breast Cancer Cells. PLoS ONE. 7(5). e37451–e37451. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact